History
2011
April 28
The official date of NANOLEK incorporation
2012
July 26
July 26 – start of construction of the NANOLEK production complex in Kirov Oblast; ground-breaking ceremony involving the Governor of Kirov Oblast
November 15
Signing of an agreement with Bilthoven Biologicals (Netherlands) on the development, technology transfer, and organization of production of the first domestic inactivated polio vaccine
December 27
The Governor of
Kirov Oblast awards NANOLEK a patronage certificate as one of the most promising investment projects
2013
2013
NANOLEK, alongside BIOCOM, wins competitions of the Ministry of Industry and Trade of the Russian Federation on the development and organization of production of chemotherapy drugs Lomustine and Procarbazine, as well as the drugs Tretinoin and Hydroxychloroquine for treating leukemia
July 30
NANOLEK, alongside the Epidbiomed Group, wins the competition of the Ministry of Industry and Trade of the Russian Federation for the transfer of foreign developments of the recombinant influenza vaccine based on virus-like particles produced using a lentiviral vector
2014
December 23
Award of a license from the Ministry of Industry and Trade of the Russian Federation for the production of sterile and non-sterile medicinal products; official launch ceremony for the production of solid dosage forms (building 5)
2015
March 26
Signing of an agreement with biotechnology company Green Cross (Republic of Korea) on strategic partnership for the development and production of high-tech biopharmaceuticals
June
Launch of serial production of solid dosage forms at the NANOLEK plant in Kirov Oblast
June 19
Signing of an agreement with Sanofi Pasteur to localize the 5-component combination vaccine Pentaxim®
September 7
Signing of an agreement with EGIS and Celltrion (Korea) to localize the rheumatoid arthritis drug Flammegis®, a biosimilar of Infliximab
September 19
Award of international and Russian ISO 9001 quality certification
October 2
Signing of an agreement with Merck to localize the production of drugs to treat diabetes and cardiovascular diseases (Glucophage, Concor)
2016
March 17
Conclusion of an agreement with Aspen to localize the low molecular weight heparin Fraxiparine (nadroparin calcium), a leading drug in the thromboprophylaxis segment in Russia, at the NANOLEK plant
April 22
Award of a patronage certificate by the Governor of Kirov oblast
September 27
Signing of strategic partnership agreement with TEVA (Israel)
November 11
Launch of biotechnological production (including manufacture of inactivated polio vaccine (IPV)
December 26
Completion of the first phase of clinical trials of an innovative influenza vaccine
2017
March 1
Assignment by Russian Ministry of Health of orphan status to the drug Hunterase (Idursulfase)
March 21
Signing of cooperation agreement with the National Immunobiological Company
April 13
Launch of a second line of solid dosage forms and a line for small-batch production
April 27
Launch of cooperation with pharmaceutical company RIEMSER Pharma GmbH (Germany)
May
Approval granted for the second and third phase of clinical trials into an innovative influenza vaccine
August
Extension of IS0 9001 certificate for full-cycle production of biotechnology drugs
September 5
Signing of an agreement with SK Chemicals (South Korea) for the development and production of vaccines
December 7
Release of the latest series of the inactivated polio vaccine for the National Vaccination Schedule, to cater for the 2017 supply requirement
2018
March
Green Cross (South Korea) and NANOLEK register a drug in Russia for treatment of Hunter syndrome
July 16
Signing of a cooperation agreement between NANOLEK, the Government of Kirov Oblast, VyatSU, and Kirov State Medical University (KSMU), for the creation of a Regional Center for Clinical Research, which will enable the launch of full-cycle production of domestic drugs in Kirov Oblast
July 27
NANOLEK once again confirms conformity of its quality management system to the best international standards and obtains updated ISO 9001:2015, GOST R ISO 9001:2015 and IQ Net certificates pertaining to the transfer, production, packaging, storage and release of sterile and non-sterile drugs, including vaccines, blood products, immunomodulators, monoclonal antibodies, and cytokines
December 12
NANOLEK and the German pharmaceutical company Merck launch full-cycle production of prediabetes and Type-2 diabetes mellitus drugs
2019
February 11
NANOLEK registers an HIV drug (Atazanavir-Nanolek) in the State Register of Medicinal Products
March
NANOLEK announces the start of clinical trials of a vaccine against pneumococcal infections; the project will facilitate the uninterrupted provision of a highly effective and safe drug, included in the list of the National Vaccination Schedule (NVS), to citizens of the Russian Federation and the CIS
April
NANOLEK becomes a member of the Developing Countries Vaccine Manufacturers Network (DCVMN)
June 7
NANOLEK and veterinary market leader MSD Animal Health sign an agreement for production of veterinary vaccines in Russia
July 11
NANOLEK and Chumakov Scientific Center establish joint enterprise Invac to manufacture a domestic inactivated polio vaccine (IPV)
August 14
NANOLEK withdraws from the list of RUSNANO portfolio companies
September 16
NANOLEK and the international company GSK signed an agreement on long-term strategic partnership in the field of the vaccine production in Russian Federation
October 15
NANOLEK and Janssen, a pharmaceutical products division of Johnson & Johnson LLC, announced the localization in Russia of the production of Darzalex® (daratumumab) used in the treatment of multiple myeloma
November
NANOLEK and Sanofi are signing a Memorandum of Intent on the start of a new project to localize the production of a combined conjugate vaccine for the prevention of meningococcal infection
DECEMBER 10
NANOLEK and Merck announce the start of a full production cycle for the manufacture of "Concor" to treat arterial hypertension, coronary heart disease and chronic heart failure.
